Table 1 Characteristics of Ph + leukemia survivors by diagnosis
CML (N = 44) | Ph + ALL (N = 22) | |
|---|---|---|
N (%) | N (%) | |
Clinical Characteristics | ||
Sex | ||
Male | 21 (47.7) | 12 (54.5) |
Female | 23 (52.3) | 10 (45.5) |
Race and ethnicity | ||
White non-Hispanic | 11 (25.0) | 7 (31.8) |
Black non-Hispanic | 12 (27.3) | 3 (13.6) |
Hispanic | 5 (11.4) | 8 (36.4) |
Asian | 14 (31.8) | 2 (9.1) |
Other/Not Stated | 2 (4.5) | 2 (9.1) |
Age at diagnosis, years | 13 (3, 20)* | 11 (3, 20)* |
Age at censoring, years | 19 (6, 35)* | 17.5 (6, 26)* |
Time under observation, years | 6.3 (1.1, 15.8)* | 5.7 (2.1, 11.8)* |
Treatment Information | ||
Tyrosine kinase inhibitor | ||
Imatinib | 35 (79.5) | 14 (63.6) |
Dasatinib | 26 (59.1) | 16 (72.7) |
Nilotinib | 7 (15.9) | 0 (0.0) |
Ponatinib | 2 (4.5) | 0 (0.0) |
Bosutinib | 1 (2.3) | 0 (0.0) |
More than one TKI | 21 (47.7) | 8 (36.4) |
Duration of TKI treatment, yearsa | 6.3 (0.9, 15.6)* | 2.8 (0.6, 11.6)* |
Cranial radiation | ||
Yes | 0 (0.0) | 6 (27.3) |
No | 44 (100.0) | 16 (72.7) |
Clinical trial enrollment | ||
Enrolled | 6 (13.6) | 9 (40.9) |
Not enrolled | 38 (86.4) | 13 (59.1) |